Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients

Figure 2

Serum values of IL-6 and anti-HCV antibodies. Patients were divided into four groups, based on kidney function and hepatitis C viral infection. Serum levels of cytokines were determined by ELISA. (a, b, c) There were no significant difference in serum levels of IL-1β, IL-23, and IL-4. (d) Anti-HCV antibodies were measured in sera of ESRD HCV⁺ and HCV⁺ patients. Significant difference was not observed in the level of anti-HCV antibodies in ESRD HCV⁺ patients compared to HCV⁺ patients. Anti-HCV antibodies were determined by ELISA. (e) Increased serum concentration of IL-6 in ESRD patients compared to the healthy control as well as in ESRD HCV⁺ patients compared to HCV⁺ patients.

(a)

(b)

(c)

(d)

(e)